These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20920543)

  • 1. Paliperidone-induced leukopenia and neutropenia: a case report.
    Kim JN; Lee BC; Choi IG; Jon DI; Jung MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):284-5. PubMed ID: 20920543
    [No Abstract]   [Full Text] [Related]  

  • 2. Risperidone/paliperidone induced neutropenia and lymphopenia.
    Raj V; Druitt T; Purushothaman S; Dunsdon J
    Aust N Z J Psychiatry; 2013 Mar; 47(3):291-2. PubMed ID: 22984110
    [No Abstract]   [Full Text] [Related]  

  • 3. Choreatic symptoms during and after treatment with paliperidone and escitalopram.
    Hüther R; Gebhart C; Mirisch S; Bäuml J; Förstl H
    Pharmacopsychiatry; 2008 Sep; 41(5):203-4. PubMed ID: 18763225
    [No Abstract]   [Full Text] [Related]  

  • 4. Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to paliperidone.
    Hsu WY; Chiu NY
    J Clin Psychopharmacol; 2013 Oct; 33(5):712-3. PubMed ID: 23899637
    [No Abstract]   [Full Text] [Related]  

  • 5. Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.
    Liang CS; Yang FW; Huang YC
    J Clin Psychopharmacol; 2012 Oct; 32(5):720-1. PubMed ID: 22926613
    [No Abstract]   [Full Text] [Related]  

  • 6. Paliperidone-induced mania-like symptoms: a case report.
    Wang WT; Chen CH; Lu ML; Lai TJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1351-2. PubMed ID: 20600461
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
    Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
    J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report.
    Matsuura H; Kimoto S; Harada I; Naemura S; Yamamuro K; Kishimoto T
    BMC Psychiatry; 2016 May; 16():161. PubMed ID: 27229149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is aripiprazole the only choice of treatment of the patients who developed anti-psychotic agents-induced leucopenia and neutropenia? A case report.
    Yalcin DO; Goka E; Aydemir MC; Kisa C
    J Psychopharmacol; 2008 May; 22(3):333-5. PubMed ID: 18208928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E36-7. PubMed ID: 24763786
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
    Teng PR; Lane HY
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E16-7. PubMed ID: 22231327
    [No Abstract]   [Full Text] [Related]  

  • 12. Manic symptoms induced by paliperidone.
    Hsieh CH; Liou YJ
    J Clin Psychopharmacol; 2010 Apr; 30(2):202-4. PubMed ID: 20520298
    [No Abstract]   [Full Text] [Related]  

  • 13. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
    Han C; Lee SJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):650-1. PubMed ID: 21163319
    [No Abstract]   [Full Text] [Related]  

  • 14. Leukopenia and neutropenia induced by quetiapine.
    Cowan C; Oakley C
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):292-4. PubMed ID: 16930797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone-related rabbit syndrome.
    Teng PR; Lai TJ
    J Clin Psychopharmacol; 2011 Jun; 31(3):379-80. PubMed ID: 21532365
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible neuroleptic malignant syndrome during paliperidone administration: a case report.
    Mantas C; Kalabokis G; Goulia P; Tourlakopoulos A; Hyphantis T; Mavreas V
    J Clin Psychopharmacol; 2010 Feb; 30(1):89-91. PubMed ID: 20075663
    [No Abstract]   [Full Text] [Related]  

  • 17. Paliperidone-induced tardive dystonia: a case report.
    Havaki-Kontaxaki B; Karaiskos D; Pappa D; Papadimitriou GN
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):E51. PubMed ID: 23686064
    [No Abstract]   [Full Text] [Related]  

  • 18. Paliperidone overdose in a patient with schizophrenia.
    Chang JP; Huang CC; Su KP
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):418. PubMed ID: 19995588
    [No Abstract]   [Full Text] [Related]  

  • 19. Catatonia and encephalopathy associated with paliperidone palmitate.
    Coffey MJ
    J Clin Psychopharmacol; 2012 Apr; 32(2):284-5. PubMed ID: 22388156
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral-paliperidone-induced tardive dyskinesia: a case report.
    Wei HT; Lai YW; Chen MH; Chen YS
    Gen Hosp Psychiatry; 2012; 34(5):578.e5-6. PubMed ID: 22154659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.